Microsoft Excel LibreOffice Calc

Eli Lilly & Co. (LLY)


Analysis of Long-term (Investment) Activity Ratios

Low level of difficulty


Long-term Activity Ratios (Summary)

Eli Lilly & Co., long-term (investment) activity ratios

Microsoft Excel LibreOffice Calc
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Net fixed asset turnover 2.75 2.59 2.57 2.48 2.46
Total asset turnover 0.56 0.51 0.55 0.56 0.53
Equity turnover 2.50 1.97 1.52 1.37 1.28

Based on: 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-19).

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Eli Lilly & Co.’s net fixed asset turnover ratio improved from 2016 to 2017 and from 2017 to 2018.
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Eli Lilly & Co.’s total asset turnover ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level.
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Eli Lilly & Co.’s equity turnover ratio improved from 2016 to 2017 and from 2017 to 2018.

Net Fixed Asset Turnover

Eli Lilly & Co., net fixed asset turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (US$ in thousands)
Revenue 24,555,700  22,871,300  21,222,100  19,958,700  19,615,600 
Property and equipment, net 8,919,500  8,826,500  8,252,600  8,053,500  7,963,900 
Long-term Activity Ratio
Net fixed asset turnover1 2.75 2.59 2.57 2.48 2.46
Benchmarks
Net Fixed Asset Turnover, Competitors2
Abbott Laboratories 4.04 3.60 3.66 3.56 3.41
AbbVie Inc. 11.36 10.07 9.85 8.91 8.03
Allergan PLC 8.83 8.93 9.04 9.58 8.19
Amgen Inc. 4.54 4.37 4.41 4.27 3.70
Biogen Inc. 3.74 3.86 4.58 4.92 5.50
Bristol-Myers Squibb Co. 4.49 4.15 3.90 3.75 3.59
Celgene Corp. 11.17 12.12 12.03 11.25 11.77
Gilead Sciences Inc. 5.41 7.79 10.45 14.13 14.62
Johnson & Johnson 4.79 4.50 4.52 4.41 4.61
Merck & Co. Inc. 3.18 3.23 3.31 3.16 3.22
Pfizer Inc. 4.01 3.79 3.97 3.55 4.22
Regeneron Pharmaceuticals Inc. 2.61 2.49 2.33 2.57 2.89
Net Fixed Asset Turnover, Sector
Pharmaceuticals & Biotechnology 4.44 4.31 4.44 4.33 4.33
Net Fixed Asset Turnover, Industry
Health Care 6.21 6.00 6.22 5.82 5.71

Based on: 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-19).

1 2018 Calculation
Net fixed asset turnover = Revenue ÷ Property and equipment, net
= 24,555,700 ÷ 8,919,500 = 2.75

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Eli Lilly & Co.’s net fixed asset turnover ratio improved from 2016 to 2017 and from 2017 to 2018.

Total Asset Turnover

Eli Lilly & Co., total asset turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (US$ in thousands)
Revenue 24,555,700  22,871,300  21,222,100  19,958,700  19,615,600 
Total assets 43,908,400  44,981,000  38,805,900  35,568,900  37,178,200 
Long-term Activity Ratio
Total asset turnover1 0.56 0.51 0.55 0.56 0.53
Benchmarks
Total Asset Turnover, Competitors2
Abbott Laboratories 0.46 0.36 0.40 0.49 0.49
AbbVie Inc. 0.55 0.40 0.39 0.43 0.72
Allergan PLC 0.16 0.13 0.11 0.11 0.25
Amgen Inc. 0.34 0.27 0.28 0.29 0.28
Biogen Inc. 0.53 0.52 0.50 0.55 0.68
Bristol-Myers Squibb Co. 0.64 0.62 0.58 0.52 0.47
Celgene Corp. 0.43 0.43 0.40 0.34 0.44
Gilead Sciences Inc. 0.34 0.37 0.53 0.62 0.71
Johnson & Johnson 0.53 0.49 0.51 0.53 0.57
Merck & Co. Inc. 0.51 0.46 0.42 0.39 0.43
Pfizer Inc. 0.34 0.31 0.31 0.29 0.29
Regeneron Pharmaceuticals Inc. 0.57 0.67 0.70 0.73 0.73
Total Asset Turnover, Sector
Pharmaceuticals & Biotechnology 0.42 0.37 0.38 0.38 0.44
Total Asset Turnover, Industry
Health Care 0.54 0.48 0.49 0.46 0.54

Based on: 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-19).

1 2018 Calculation
Total asset turnover = Revenue ÷ Total assets
= 24,555,700 ÷ 43,908,400 = 0.56

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Eli Lilly & Co.’s total asset turnover ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level.

Equity Turnover

Eli Lilly & Co., equity turnover calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (US$ in thousands)
Revenue 24,555,700  22,871,300  21,222,100  19,958,700  19,615,600 
Total Eli Lilly and Company shareholders’ equity 9,828,700  11,592,200  14,007,700  14,571,300  15,373,200 
Long-term Activity Ratio
Equity turnover1 2.50 1.97 1.52 1.37 1.28
Benchmarks
Equity Turnover, Competitors2
Abbott Laboratories 1.00 0.89 1.02 0.96 0.94
AbbVie Inc. 5.54 5.53 5.79 11.46
Allergan PLC 0.24 0.22 0.19 0.20 0.46
Amgen Inc. 1.80 0.86 0.73 0.75 0.75
Biogen Inc. 1.03 0.97 0.94 1.15 0.90
Bristol-Myers Squibb Co. 1.61 1.77 1.20 1.16 1.07
Celgene Corp. 2.48 1.87 1.69 1.55 1.16
Gilead Sciences Inc. 1.01 1.26 1.59 1.73 1.59
Johnson & Johnson 1.37 1.27 1.02 0.98 1.07
Merck & Co. Inc. 1.58 1.17 0.99 0.88 0.87
Pfizer Inc. 0.85 0.74 0.89 0.75 0.70
Regeneron Pharmaceuticals Inc. 0.77 0.96 1.09 1.12 1.11
Equity Turnover, Sector
Pharmaceuticals & Biotechnology 1.19 0.98 0.93 0.88 0.96
Equity Turnover, Industry
Health Care 1.41 1.23 1.19 1.08 1.19

Based on: 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19), 10-K (filing date: 2015-02-19).

1 2018 Calculation
Equity turnover = Revenue ÷ Total Eli Lilly and Company shareholders’ equity
= 24,555,700 ÷ 9,828,700 = 2.50

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Eli Lilly & Co.’s equity turnover ratio improved from 2016 to 2017 and from 2017 to 2018.